Sovleplenib is an investigational new drug that is being evaluated by Hutchison MediPharma for the treatment of immune thrombocytopenia (ITP) and warm antibody autoimmune hemolytic anemia (WAIHA). It has also been shown preclinically to have activity against B-cell lymphoma. Sovleplenib is a tyrosine-protein kinase SYK inhibitor.
Clinical trials Sovleplenib has completed a phase 3 clinical trial for ITP. Another phase 3 trial for WAIHA is on going.
References


